GlassScriptPhysician profile
Alyssa M Kuban
NPI 1629373659
$1,217.52
in general payments reported to CMS, 2019-2025
12 companies · $16.03 in 2025
The $16.03 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $55.68 · 2021: $122 · 2022: $205 · 2023: $302 · 2024: $269 · 2025: $16.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $259.76 | 2019-2024 | Jornay Pm |
| Corium, LLC | $225.67 | 2021-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $205.71 | 2021-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $180.75 | 2019-2024 | Doc Band |
| Merck Sharp & Dohme LLC | $79.16 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $78.17 | 2019-2020 | |
| Sobi, INC | $54.07 | 2019-2022 | |
| Rhodes Pharmaceuticals L.P. | $37.06 | 2019 | |
| Shire North American Group INC | $36.57 | 2019 | |
| Biomarin Pharmaceutical INC. | $26.68 | 2024 | Voxzogo 1.2mg |
| Sanofi-Aventis U.S. LLC | $20.63 | 2023 | |
| Neos Therapeutics, LP | $13.29 | 2024 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Kuban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.